Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

NCT02848326 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

834

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine, With or Without Aura

Interventions

DRUG: Atogepant
DRUG: Placebo-matching Atogepant

Sponsor

Allergan